A ge­net­ics test­ing out­fit is bail­ing on its CRO ser­vices, choos­ing in­stead to re­fo­cus around pre­ci­sion drugs

In the past few months, there’s been a string of con­sol­i­da­tion in the CRO space, with big play­ers merg­ing to­geth­er and head­line names in con­tract man­u­fac­tur­ing snap­ping up re­search teams. But a Texas ge­net­ics play­er is now go­ing the oth­er way, bail­ing on its CRO of­fer­ings to in­stead fo­cus on pre­ci­sion med­i­cine.

Salt Lake City-based Myr­i­ad is sell­ing its Austin con­tract re­search lab to North Car­oli­na’s Q2 So­lu­tions, the com­pa­ny said Mon­day. The deal is ex­pect­ed to be closed in Q3 and will al­low Myr­i­ad to fo­cus ef­forts on women’s health, on­col­o­gy and men­tal health, CEO Paul Di­az said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER